ReviewZhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery2026
[Advances in application of hydrogels for treatment of osteonecrosis of the femoral head].
Review in Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To summarize recent research advances of hydrogels for the treatment of osteonecrosis of the femoral head (ONFH). Methods: The literature on hydrogels for treatment of ONFH at home and abroad in recent years was extensively reviewed, and the fundamental research and clinical application were summarized and analyzed. Results: In the field of fundamental research, functionalized hydrogels (including thermosensitive, oxygen-controlled release, and ion-doped types) demonstrate significant advantages in achieving targeted delivery, controlled release, and microenvironment regulation. Particularly, the development of novel material systems, such as composite scaffold systems, gene-activated hydrogels, and engineered exosomes, has further enhanced treatment precision and biological efficacy. In terms of clinical application, the materials like recombinant human fibroblast growth factor 2 (rhFGF-2) gelatin hydrogels have been validated in multiple trials, showing promising joint preservation rates and bone regeneration capabilities. This opens a promising new clinical pathway for hip-preserving treatment of ONFH. Among these, hydrogel-based multilevel composite scaffolds represent the most promising materials for clinical translation. Conclusion: Hydrogel systems, by synergistically regulating osteogenesis, angiogenesis, and immunomodulation, and leveraging the unique advantages of functionalized materials in precise drug control and microenvironment regulation, have evolved into advanced platforms for the comprehensive treatment of ONFH. Among them, rhFGF-2 gelatin hydrogels, with their remarkable clinical efficacy, offer a new strategy of significant translational value for hip-preserving therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.